Skip to main content
Premium Trial:

Request an Annual Quote

Matthias Mann, Williams Sims, Matthew Fust, Russell Singleton, David Busam, Alan Barber, Karen Vaccaro, Gary Fagan

Premium

Matthias Mann will move to Munich to become a director at the Max Planck Institute for Biochemistry, effective May 1, 2005, Mann confirmed this week. He is currently the director of the Center for Experimental Bioinformatics at the University of Southern Denmark in Odense.


Williams Sims has become Mountain View, Calif.-based Perlegen Sciences’ new chief financial officer. He replaces Matthew Fust, who has joined Jazz Pharmaceuticals as CFO. Sims comes to Perlegen from Clontech Laboratories, where he was CFO until its acquisition by Becton Dickinson, when he became vice president of finance and business operations. He holds an MBA from the Stanford University Graduate School of Business and a bachelor of science in business from Oregon State University.

Also, Russell Singleton has become vice president, engineering and informatics at Perlegen. Prior to joining Perlegen, Singleton worked at KLA-Tencor. Previously, he headed up instrumentation and software development programs at Molecular Dynamics. He holds a bachelor’s in electrical engineering from the Pratt Institute, and a PhD in electrical engineering from the University of Illinois.


David Busam has become chief financial officer, as well as vice president of finance and administration, at Evergreen, Colo.-based CeMines. Prior to joining CeMines, Busam was senior director of corporate finance at Denver-based Qwest Communications International. Busam holds an MBA and a BS in finance from Auburn University.


Alan Barber has become chief financial officer at Woburn, Mass.-based BioTrove. Prior to that he was CFO at Omnisonics Medical Technologies. Barber holds a BS in accounting from Florida State University.


Karen Vaccaro will retire as vice president for R&D of Newton, Mass.-based Matritech on June 25. She will continue to advise the company. While Matritech is searching for a successor, Gary Fagan, senior director for product development, will serve as acting chief scientific officer.